Product Description: Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer[1][2][3][4].
Applications: Cancer-Kinase/protease
Formula: C31H26ClF4N7O2
References: [1]Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1./[2]Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J]. 2024./[3]Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. J Med Chem. 2024 Aug 22;67(16):13534-13549. /[4]Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J]. 2024.
CAS Number: 2657613-87-9
Molecular Weight: 640.03
Compound Purity: 99.20
Research Area: Cancer
Solubility: DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Ras
English
Deutsch
